Abstract:Background: Cancer remains one of the leading causes of mortality globally, with conventional chemotherapy often resulting in severe side effects and limited effectiveness. Recent advancements in bioinformatics and machine learning, particularly deep learning, offer promising new avenues for cancer treatment through the prediction and identification of anticancer peptides. Objective: This study aimed to develop and evaluate a deep learning model utilizing a two-dimensional convolutional neural network (2D CNN) to enhance the prediction accuracy of anticancer peptides, addressing the complexities and limitations of current prediction methods. Methods: A diverse dataset of peptide sequences with annotated anticancer activity labels was compiled from various public databases and experimental studies. The sequences were preprocessed and encoded using one-hot encoding and additional physicochemical properties. The 2D CNN model was trained and optimized using this dataset, with performance evaluated through metrics such as accuracy, precision, recall, F1-score, and area under the receiver operating characteristic curve (AUC-ROC). Results: The proposed 2D CNN model achieved superior performance compared to existing methods, with an accuracy of 0.87, precision of 0.85, recall of 0.89, F1-score of 0.87, and an AUC-ROC value of 0.91. These results indicate the model's effectiveness in accurately predicting anticancer peptides and capturing intricate spatial patterns within peptide sequences. Conclusion: The findings demonstrate the potential of deep learning, specifically 2D CNNs, in advancing the prediction of anticancer peptides. The proposed model significantly improves prediction accuracy, offering a valuable tool for identifying effective peptide candidates for cancer treatment. Future work: Further research should focus on expanding the dataset, exploring alternative deep learning architectures, and validating the model's predictions through experimental studies. Efforts should also aim at optimizing computational efficiency and translating these predictions into clinical applications.

Efficient Mining of Anticancer Peptides from Gut Metagenome (Adv. Sci. 25/2023)

Efficient Mining of Anticancer Peptides from Gut Metagenome

Genomic Data Mining Approaches for the Discovery of Anticancer Peptides from Ganoderma Sinense.

Identification of antimicrobial peptides from the human gut microbiome using deep learning

Metaverse Applications in Bioinformatics: A Machine Learning Framework for the Discrimination of Anti-Cancer Peptides

Integrating In Silico and In Vitro Approaches to Identify Natural Peptides with Selective Cytotoxicity against Cancer Cells

Machine Learning-Driven Discovery and Evaluation of Antimicrobial Peptides from Crassostrea gigas Mucus Proteome

ACPScanner: Prediction of Anticancer Peptides by Integrated Machine Learning Methodologies

Discovering and Validating Neoantigens by Mass Spectrometry-based Immunopeptidomics and Deep Learning

DeepAntigen: a novel method for neoantigen prioritization via 3D genome and deep sparse learning

Identification of potent antimicrobial peptides via a machine-learning pipeline that mines the entire space of peptide sequences

Efficient prediction of anticancer peptides through deep learning

Methylation Landscape: Targeting Writer or Eraser to Discover Anti-Cancer Drug

Identification and functional analysis of phycocyanin-derived bioactive peptides with non-small cell lung cancer cell inhibition

HMPA: a pioneering framework for the noncanonical peptidome from discovery to functional insights

Decoding the glycoproteome: a new frontier for biomarker discovery in cancer

Artificial Intelligence Approach to Find Lead Compounds for Treating Tumors

Exploring the seas for cancer cures: the promise of marine-derived bioactive peptide

Developing Anticancer Drug Response System Using Deep Learning System with Hybrid Genomic and Chemical Features

A powerful machine learning approach to identify interactions of differentially abundant gut microbial subsets in patients with metastatic and non-metastatic pancreatic cancer

Predicting cancer immunotherapy response from gut microbiomes using machine learning models